Matrix metalloproteinase-3 gene polymorphism and its mRNA expression in rheumatoid arthritis

Mj, Ma; Hc, Liu; Xq, Qu; Jl, Wang

doi:10.4238/2015.december.1.17

Cited by 14 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, matrix metalloproteinase-3 gene polymorphism could also explain the differences mentioned above. It has been shown recently shown that the degree and rate of bone erosion damage are higher in RA patients with the 6A/6A genotype [27]. Ally et al [24] studied 128 DMARDs-naïve early RA patients and also So et al [22] in one of the earliest studies, did not find a correlation between levels of MMP-3 and erosions detected by X-ray similar to our results.…”

Section: Discussionsupporting

confidence: 60%

“…Ally et al [24] studied 128 DMARDs-naïve early RA patients and also So et al [22] in one of the earliest studies, did not find a correlation between levels of MMP-3 and erosions detected by X-ray similar to our results. Serum levels of MMP-3 were significantly elevated in RA patients [28,29] and strongly correlated with the levels of CRP and ESR [22][23][24]27]. In our group, 73% of early RA patients showed increased levels of MMP-3, which were strongly correlated with the parameters of disease activity (ESR, CRP, DAS-28) and patients' disability (HAQ).…”

Section: Discussionsupporting

confidence: 48%

See 1 more Smart Citation

Matrix Metalloproteinases-3 Baseline Serum Levels in Early Rheumatoid Arthritis Patients without Initial Radiographic Changes: A Two-Year Ultrasonographic Study

et al. 2018

View full text Add to dashboard Cite

Objective: To investigate the association of high baseline serum levels of metalloproteinases-3 (MMP-3) with structural damage to hand and feet joints, assessed by ultrasonography (US), in patients with early, treatment-naïve rheumatoid arthritis (RA), without initial X-ray-visible erosions, during 24 months follow-up. Methods: Sixty-three early RA (European League Against Rheumatism/American College of Rheumatology 2010), disease-modifying anti-rheumatic drugs/glucocorticoid naïve patients (mean age 53.4 ± 14.1) with symptom duration ≤12 months, had baseline serum levels of MMP-3 tested. OMERACT US group definition was used to detect the presence, as well as longitudinal diameter of erosions by US at study entry and after 24 months, at the level of wrists, metacarpophalangeal (MCP2/MCP5) joints of both hands, and fifth metatarsophalangeal joints. Results: Complete data were collected from 52 out of 63 patients. High baseline serum levels of MMP-3 (MMP-3-positive) were found in 46/63 patients. 122 bone erosions in total (1.9 bone erosions/patients) were detected by US at baseline visit and 213 erosions (4.3/patients) after 24 months. MMP-3 positive patients had significantly higher total number of erosions than MMP-3-negative (p = 0.039) and higher increase in size of bone erosions in the feet but not in the hand joints after follow-up (OR 4.82 [1.23–18.9], p = 0.024; OR 1.17 [0.320–4.26], p = 0.816 respectively). Conclusion: After 2 years of follow-up, US assessment showed a higher number of new bone erosions in MMP-3-positive compared to MMP-3-negative patients with early RA and no visible initial radiographic changes. High baseline levels of MMP-3 predict significantly higher structural damage progression at the level of feet, but not at the level of hand joints.

show abstract

Section: Discussionsupporting

confidence: 60%

Section: Discussionsupporting

confidence: 48%

Matrix Metalloproteinases-3 Baseline Serum Levels in Early Rheumatoid Arthritis Patients without Initial Radiographic Changes: A Two-Year Ultrasonographic Study

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The serum levels in patients with active RA are markedly elevated in comparison with those in remission. MMP-3 expression is regulated by a promoter gene and exhibits polymorphism with the 5A/6A alleles, but the effect of MMP-3 gene polymorphism on the development of RA is still not clear 25 . Burrage et al described the role of MMPs in the process of collagen degradation.…”

Section: Discussionmentioning

confidence: 99%

Higher levels of matrix metalloproteinase-3 in patients with RA reflect disease activity and structural damage

Skácelová¹,

Heřmanová

Horák³

et al. 2017

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

“…MMP genetic polymorphisms and levels of gene expression have been associated with several diseases, including chronic obstructive pulmonary disease, coronary heart disease, rheumatoid arthritis, and systemic lupus erythematosus (Schirmer et al, 2009;Scherer et al, 2010;Bahrehmand et al, 2015;Jiang et al, 2016;Ma et al, 2015Ma et al, , 2016. Different studies have addressed the MMP serum levels and MMP gene expression in SSc (Young-Min et al, 2001;Kikuchi et al, 2002;Toubi et al, 2002;Meng et al, 2008;Brown et al, 2012;Frost et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

Matrix metalloproteinase gene polymorphisms and susceptibility to systemic sclerosis

et al. 2016

View full text Add to dashboard Cite

ABSTRACT. The major pathological hallmark of the systemic sclerosis (SSc) is skin and internal organ fibrosis, which results from normal tissue architecture alterations and extracellular matrix (ECM) protein deposition. ECM components are degraded by matrix metalloproteinases (MMP). Promoter region polymorphisms in MMP genes may influence gene expression, resulting in an imbalance between ECM protein production and degradation. Here, we analyzed MMP1 -1607 1G/2G (rs1799750), MMP3 -1171 5A/6A (rs3025058), and MMP9 -1562 C/T 2 T.F. Rech et al. Genetics and Molecular Research 15 (4): gmr15049077(rs3918242) polymorphisms in relation to susceptibility to SSc and its clinical features. The patient group included 98 individuals with longstanding or recently diagnosed disease, meeting the American College of Rheumatology or LeRoy and Medsger criteria for SSc; the control group included 100 healthy blood donors. All participants were of European descent. Genotyping was performed by polymerase chain reaction followed by restriction digestion. Genotype and allele frequencies of MMP polymorphisms were similar between the two groups. In secondary analyses, significantly higher frequency of 1G/2G genotype from MMP1 polymorphism was observed for patients testing positive for antinuclear autoantibodies (P = 0.007), while 1G/1G genotype was associated with interstitial lung disease development (P = 0.018). The 6A/6A genotype from MMP3 polymorphism was absent in patients with calcinosis (P = 0.011), while the MMP3 5A/5A genotype correlated with the presence of anti-topoisomerase I antibodies (P = 0.009) and reduced diffusing capacity for carbon monoxide (P = 0.024). These results suggest that MMP polymorphisms are not associated with SSc susceptibility, although MMP1 and MMP3 variants are associated with specific SSc clinical and laboratory features.

show abstract

Matrix metalloproteinase-3 gene polymorphism and its mRNA expression in rheumatoid arthritis

Cited by 14 publications

References 19 publications

Matrix Metalloproteinases-3 Baseline Serum Levels in Early Rheumatoid Arthritis Patients without Initial Radiographic Changes: A Two-Year Ultrasonographic Study

Matrix Metalloproteinases-3 Baseline Serum Levels in Early Rheumatoid Arthritis Patients without Initial Radiographic Changes: A Two-Year Ultrasonographic Study

Higher levels of matrix metalloproteinase-3 in patients with RA reflect disease activity and structural damage

Matrix metalloproteinase gene polymorphisms and susceptibility to systemic sclerosis

Contact Info

Product

Resources

About